|
[1]
|
International Diabetes Federation (2025) Diabetes Facts & Figures.
https://idf.org/about-diabetes/diabetes-facts-figures/
|
|
[2]
|
International Diabetes Federation (2024) Diabetes and Kidney Disease.
https://diabetesatlas.org/atlas/diabetes-and-kidney-disease/
|
|
[3]
|
Wang, K., Xu, W., Zha, B., Shi, J., Wu, G. and Ding, H. (2021) Fibrinogen to Albumin Ratio as an Independent Risk Factor for Type 2 Diabetic Kidney Disease. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 14, 4557-4567. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Sugahara, M., Pak, W.L.W., Tanaka, T., Tang, S.C.W. and Nangaku, M. (2021) Update on Diagnosis, Pathophysiology, and Management of Diabetic Kidney Disease. Nephrology, 26, 491-500. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Alsharidah, A.S. (2022) Diabetes Mellitus and Diabetic Nephropathy: A Review of the Literature on Hemostatic Changes in Coagulation and Thrombosis. Blood Research, 57, 101-105. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Kitamoto, Y., Imamura, T., Taguma, Y., Iwaoka, T., Yorinaka, H. and Arizono, K. (2021) Urinary Thrombin as a Marker of Glomerular Inflammation Associated with Renal Injury in Type 2 Diabetes. The Tohoku Journal of Experimental Medicine, 253, 41-49. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
de Boer, I.H., Khunti, K., Sadusky, T., Tuttle, K.R., Neumiller, J.J., Rhee, C.M., et al. (2022) Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care, 45, 3075-3090. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Samsu, N. (2021) Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment. BioMed Research International, 2021, Article 1497449. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Stratton, I.M. (2000) Association of Glycaemia with Macrovascular and Microvascular Complications of Type 2 Diabetes (UKPDS 35): Prospective Observational Study. British Medical Journal, 321, 405-412. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Zoungas, S., Chalmers, J., Ninomiya, T., Li, Q., Cooper, M.E., Colagiuri, S., et al. (2011) Association of Hba1c Levels with Vascular Complications and Death in Patients with Type 2 Diabetes: Evidence of Glycaemic Thresholds. Diabetologia, 55, 636-643. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Rossing, P., Caramori, M.L., Chan, J.C.N., Heerspink, H.J.L., Hurst, C., Khunti, K., et al. (2022) KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International, 102, S1-S127. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Wiviott, S.D., Raz, I., Bonaca, M.P., Mosenzon, O., Kato, E.T., Cahn, A., et al. (2019) Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 380, 347-357. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Maruthur, N.M., Tseng, E., Hutfless, S., Wilson, L.M., Suarez-Cuervo, C., Berger, Z., et al. (2016) Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes. Annals of Internal Medicine, 164, 740-751. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Gerstein, H.C., Colhoun, H.M., Dagenais, G.R., Diaz, R., Lakshmanan, M., Pais, P., et al. (2019) Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND): A Double-Blind, Randomized Placebo-Controlled Trial. The Lancet, 394, 121-130. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Sattar, N., Lee, M.M.Y., Kristensen, S.L., Branch, K.R.H., Del Prato, S., Khurmi, N.S., et al. (2021) Cardiovascular, Mortality, and Kidney Outcomes with GLP-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Trials. The Lancet Diabetes & Endocrinology, 9, 653-662. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
de Boer, I.H., Alpers, C.E., Azeloglu, E.U., Balis, U.G.J., Barasch, J.M., Barisoni, L., et al. (2021) Rationale and Design of the Kidney Precision Medicine Project. Kidney International, 99, 498-510. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Tsimihodimos, V., Dounousi, E. and Siamopoulos, K.C. (2008) Dyslipidemia in Chronic Kidney Disease: An Approach to Pathogenesis and Treatment. American Journal of Nephrology, 28, 958-973. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Bjornstad, P., Cherney, D. and Maahs, D.M. (2014) Early Diabetic Nephropathy in Type 1 Diabetes. Current Opinion in Endocrinology, Diabetes & Obesity, 21, 279-286. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Wanner, C. and Tonelli, M. (2014) KDIGO Clinical Practice Guideline for Lipid Management in CKD: Summary of Recommendation Statements and Clinical Approach to the Patient. Kidney International, 85, 1303-1309. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Fellström, B.C., Jardine, A.G., Schmieder, R.E., Holdaas, H., Bannister, K., Beutler, J., et al. (2009) Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis. New England Journal of Medicine, 360, 1395-1407. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Zac-Varghese, S., Mark, P., Bain, S., Banerjee, D., Chowdhury, T.A., Dasgupta, I., et al. (2024) Clinical Practice Guideline for the Management of Lipids in Adults with Diabetic Kidney Disease: Abbreviated Summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2024. BMC Nephrology, 25, Article No. 216. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Elendu, C., John Okah, M., Fiemotongha, K.D.J., Adeyemo, B.I., Bassey, B.N., Omeludike, E.K., et al. (2023) Comprehensive Advancements in the Prevention and Treatment of Diabetic Nephropathy: A Narrative Review. Medicine, 102, e35397. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Cheung, A.K., Chang, T.I., Cushman, W.C., Furth, S.L., Hou, F.F., Ix, J.H., et al. (2021) KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney International, 99, S1-S87. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
American Diabetes Association Professional Practice Committee (2021) Cardiovascular Disease and Risk Management: standards of Medical Care in Diabetes 2022. Diabetes Care, 45, S144-S174. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Brenner, B.M., Cooper, M.E., de Zeeuw, D., Keane, W.F., Mitch, W.E., Parving, H., et al. (2001) Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. New England Journal of Medicine, 345, 861-869. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Keane, W.F., Brenner, B.M., de Zeeuw, D., Grunfeld, J., McGill, J., Mitch, W.E., et al. (2003) The Risk of Developing End-Stage Renal Disease in Patients with Type 2 Diabetes and Nephropathy: The RENAAL Study. Kidney International, 63, 1499-1507. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Ito, S., Kashihara, N., Shikata, K., Nangaku, M., Wada, T., Okuda, Y., et al. (2020) Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN). Clinical Journal of the American Society of Nephrology, 15, 1715-1727. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Pitt, B., Filippatos, G., Agarwal, R., Anker, S.D., Bakris, G.L., Rossing, P., et al. (2021) Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. New England Journal of Medicine, 385, 2252-2263. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Zheng, Z., Ma, T., Lian, X., Gao, J., Wang, W., Weng, W., et al. (2019) Clopidogrel Reduces Fibronectin Accumulation and Improves Diabetes-Induced Renal Fibrosis. International Journal of Biological Sciences, 15, 239-252. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Tang, W., Lin, F., Lee, C., Kuo, F., Hsieh, C., Hsiao, F., et al. (2013) Cilostazol Effectively Attenuates Deterioration of Albuminuria in Patients with Type 2 Diabetes: A Randomized, Placebo-Controlled Trial. Endocrine, 45, 293-301. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
刘婧, 王璟, 陈颖, 等. 贝前列素钠治疗糖尿病肾病患者的临床研究[J]. 中国临床药理学杂志, 2023, 39(22): 3214-3217.
|
|
[32]
|
Kim, S.K., Kim, G., Choi, B., Ryu, D., Ku, S. and Kwak, M. (2021) Negative Correlation of Urinary miR-199a-3p Level with Ameliorating Effects of Sarpogrelate and Cilostazol in Hypertensive Diabetic Nephropathy. Biochemical Pharmacology, 184, Article 114391. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
王淮淮, 赵学慧, 王会芳, 等. 基于NF-κB信号通路探讨低分子量肝素对糖尿病肾病足细胞增殖、凋亡和炎症的影响[J]. 检验医学与临床, 2024, 21(10): 1365-1370+1376.
|
|
[34]
|
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J.J., Blomström-Lundqvist, C., et al. (2020) 2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 42, 373-498. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Stevens, P.E., Ahmed, S.B., Carrero, J.J., Foster, B., Francis, A., Hall, R.K., et al. (2024) KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International, 105, S117-S314. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Fauchier, L., Boriani, G., de Groot, J.R., Kreutz, R., Rossing, P. and Camm, A.J. (2021) Medical Therapies for Prevention of Cardiovascular and Renal Events in Patients with Atrial Fibrillation and Diabetes Mellitus. EP Europace, 23, 1873-1891. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Costa, O.S., O’Donnell, B., Vardar, B., Abdelgawwad, K., Brescia, C.W., Sood, N., et al. (2021) Kidney, Limb and Ophthalmic Complications, and Death in Patients with Nonvalvular Atrial Fibrillation and Type 2 Diabetes Prescribed Rivaroxaban or Warfarin: An Electronic Health Record Analysis. Current Medical Research and Opinion, 37, 1493-1500. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Lin, S., Chen, Y., Chiang, W., Wu, K. and Tsai, T. (2008) Effect of Pentoxifylline in Addition to Losartan on Proteinuria and GFR in CKD: A 12-Month Randomized Trial. American Journal of Kidney Diseases, 52, 464-474. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Navarro-González, J.F., Sánchez-Niño, M.D., Donate-Correa, J., Martín-Núñez, E., Ferri, C., Pérez-Delgado, N., et al. (2018) Effects of Pentoxifylline on Soluble Klotho Concentrations and Renal Tubular Cell Expression in Diabetic Kidney Disease. Diabetes Care, 41, 1817-1820. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Sattarinezhad, A., Roozbeh, J., Shirazi Yeganeh, B., Omrani, G.R. and Shams, M. (2019) Resveratrol Reduces Albuminuria in Diabetic Nephropathy: A Randomized Double-Blind Placebo-Controlled Clinical Trial. Diabetes & Metabolism, 45, 53-59. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Nangaku, M., Kanda, H., Takama, H., Ichikawa, T., Hase, H. and Akizawa, T. (2020) Randomized Clinical Trial on the Effect of Bardoxolone Methyl on GFR in Diabetic Kidney Disease Patients (TSUBAKI Study). Kidney International Reports, 5, 879-890. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Ridker, P.M., MacFadyen, J.G., Glynn, R.J., Koenig, W., Libby, P., Everett, B.M., et al. (2018) Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients with Chronic Kidney Disease. Journal of the American College of Cardiology, 71, 2405-2414. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Cantero-Navarro, E., Rayego-Mateos, S., Orejudo, M., Tejedor-Santamaria, L., Tejera-Muñoz, A., Sanz, A.B., et al. (2021) Role of Macrophages and Related Cytokines in Kidney Disease. Frontiers in Medicine, 8, Article 688060. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Tan, S.M., Snelson, M., Østergaard, J.A. and Coughlan, M.T. (2022) The Complement Pathway: New Insights into Immunometabolic Signaling in Diabetic Kidney Disease. Antioxidants & Redox Signaling, 37, 781-801. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Liu, H., Dear, A.E., Knudsen, L.B. and Simpson, R.W. (2009) A Long-Acting Glucagon-Like Peptide-1 Analogue Attenuates Induction of Plasminogen Activator Inhibitor Type-1 and Vascular Adhesion Molecules. Journal of Endocrinology, 201, 59-66. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Chen, Y., Su, M., Walia, R.R., Hao, Q., Covington, J.W. and Vaughan, D.E. (1998) Sp1 Sites Mediate Activation of the Plasminogen Activator Inhibitor-1 Promoter by Glucose in Vascular Smooth Muscle Cells. Journal of Biological Chemistry, 273, 8225-8231. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Placencio, V.R. and DeClerck, Y.A. (2015) Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing. Cancer Research, 75, 2969-2974. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Vaughan, D.E., Rai, R., Khan, S.S., Eren, M. and Ghosh, A.K. (2017) Plasminogen Activator Inhibitor-1 Is a Marker and a Mediator of Senescence. Arteriosclerosis, Thrombosis, and Vascular Biology, 37, 1446-1452. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Flevaris, P. and Vaughan, D. (2016) The Role of Plasminogen Activator Inhibitor Type-1 in Fibrosis. Seminars in Thrombosis and Hemostasis, 43, 169-177. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Simone, T.M., Longmate, W.M., Law, B.K. and Higgins, P.J. (2015) Targeted Inhibition of PAI-1 Activity Impairs Epithelial Migration and Wound Closure Following Cutaneous Injury. Advances in Wound Care, 4, 321-328. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Altalhi, R., Pechlivani, N. and Ajjan, R.A. (2021) PAI-1 in Diabetes: Pathophysiology and Role as a Therapeutic Target. International Journal of Molecular Sciences, 22, Article 3170. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Rouch, A., Vanucci-Bacqué, C., Bedos-Belval, F. and Baltas, M. (2015) Small Molecules Inhibitors of Plasminogen Activator Inhibitor-1—An Overview. European Journal of Medicinal Chemistry, 92, 619-636. [Google Scholar] [CrossRef] [PubMed]
|
|
[53]
|
Miyazaki, H., Sai, H., Ohmizu, H., Murakami, J., Ohtani, A. and Ogiku, T. (2010) Synthesis and Evaluation of 1,4-Diphenylbutadiene Derivatives as Inhibitors of Plasminogen Activator Inhibitor-1 (PAI-1) Production. Bioorganic & Medicinal Chemistry, 18, 1968-1979. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Miyazaki, H., Ogiku, T., Sai, H., Ohmizu, H., Murakami, J. and Ohtani, A. (2008) Design, Synthesis, and Evaluation of Orally Active Inhibitors of Plasminogen Activator Inhibitor-1 (PAI-1) Production. Bioorganic & Medicinal Chemistry Letters, 18, 6419-6422. [Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Biemond, B.J., Levi, M., Coronel, R., Janse, M.J., Cate, J.W.T. and Pannekoek, H. (1995) Thrombolysis and Reocclusion in Experimental Jugular Vein and Coronary Artery Thrombosis. Circulation, 91, 1175-1181. [Google Scholar] [CrossRef] [PubMed]
|
|
[56]
|
Vousden, K.A., Lundqvist, T., Popovic, B., Naiman, B., Carruthers, A.M., Newton, P., et al. (2019) Discovery and Characterisation of an Antibody That Selectively Modulates the Inhibitory Activity of Plasminogen Activator Inhibitor-1. Scientific Reports, 9, Article No. 1605. [Google Scholar] [CrossRef] [PubMed]
|
|
[57]
|
Elokdah, H., Abou-Gharbia, M., Hennan, J.K., McFarlane, G., Mugford, C.P., Krishnamurthy, G., et al. (2004) Tiplaxtinin, a Novel, Orally Efficacious Inhibitor of Plasminogen Activator Inhibitor-1: Design, Synthesis, and Preclinical Characterization. Journal of Medicinal Chemistry, 47, 3491-3494. [Google Scholar] [CrossRef] [PubMed]
|
|
[58]
|
Gorlatova, N.V., Cale, J.M., Elokdah, H., Li, D., Fan, K., Warnock, M., et al. (2007) Mechanism of Inactivation of Plasminogen Activator Inhibitor-1 by a Small Molecule Inhibitor. Journal of Biological Chemistry, 282, 9288-9296. [Google Scholar] [CrossRef] [PubMed]
|
|
[59]
|
Fortenberry, Y.M. (2013) Plasminogen Activator Inhibitor-1 Inhibitors: A Patent Review (2006-Present). Expert Opinion on Therapeutic Patents, 23, 801-815. [Google Scholar] [CrossRef] [PubMed]
|
|
[60]
|
Sarker, B., Cardona, S.M., Church, K.A., Vanegas, D., Velazquez, P., Rorex, C., et al. (2022) Defibrinogenation Ameliorates Retinal Microgliosis and Inflammation in a CX3CR1-Independent Manner. ASN Neuro, 14, Article 17590914221131446. [Google Scholar] [CrossRef] [PubMed]
|
|
[61]
|
Tuttle, K.R., Agarwal, R., Alpers, C.E., Bakris, G.L., Brosius, F.C., Kolkhof, P., et al. (2022) Molecular Mechanisms and Therapeutic Targets for Diabetic Kidney Disease. Kidney International, 102, 248-260. [Google Scholar] [CrossRef] [PubMed]
|
|
[62]
|
Abu Seman, N. and Othman, S.H. (2023) Recent Progress in Genetics and Epigenetics Research on Diabetic Nephropathy in Malaysia. Journal of Diabetes Research, 2023, 1-8. [Google Scholar] [CrossRef] [PubMed]
|